肌腱炎治疗市场 - 依治疗（治疗、手术、药物）、应用（阿基里斯腱炎、冈上肌腱炎、网球肘、投手肘、跳投膝）、配销通路、最终用途 - 全球预测 2024 - 2032

在领先公司不断加强研发力度的推动下，2024 年至 2032 年间，全球肌腱炎治疗市场复合年增长率将达到 3.8%。由于肌腱炎是一种影响全球数百万人的普遍疾病，因此越来越需要能够提供有效缓解和更快恢復的创新治疗方法。

例如，2023 年 6 月，梅奥诊所的物理医学和復健专家正在利用超音波引导进行经皮腱切断术，采用高压盐水流来治疗慢性肌腱病患者。这种门诊手术称为经皮加压水腱切开术，不需要全身麻醉。

领先的製药和生技公司正在大力投资研发，以开发新型疗法，包括再生医学方法和先进的药物配方。此外，穿戴式装置和微创手术等技术进步正在重塑肌腱炎治疗的模式。随着这些努力取得了可喜的成果，肌腱炎治疗市场有望显着成长，为患者带来希望，并推动针对这种常见疾病的医疗保健解决方案的发展。

整个肌腱炎治疗行业根据治疗、应用、配销通路、最终用途和地区进行分类。

2024年至2032年，手术部分将经历显着发展。经皮腱切断术或肌腱修復术等手术为恢復肌腱功能和减轻症状提供了有效的解决方案。随着微创技术的进步和手术效果的改善，患者和医疗保健提供者越来越倾向于手术治疗。因此，肌腱炎治疗市场对手术介入的需求持续扩大，满足了寻求长期缓解和提高生活品质的个人的需求。

从2024 年到2032 年，冈上肌腱炎细分市场的肌腱炎治疗市场份额将出现显着的复合年增长率。并恢復功能。保守方法（例如休息、物理治疗和非类固醇抗发炎药）以及更先进的治疗方法（包括皮质类固醇注射或手术干预）都旨在解决这种情况。为了减轻疼痛并改善肩部活动能力，肌腱炎治疗市场对针对冈上肌腱炎的创新和客製化治疗的需求仍然很高。

亚太地区肌腱炎治疗市场从2024 年到2032 年将呈现出值得称讚的复合年增长率。对有效治疗方案的需求日益增长。此外，医疗保健意识的提高、医疗设施的改善以及治疗方式的进步都有助于扩大市场需求。随着亚太地区医疗基础设施的不断发展，对肌腱炎治疗的需求可能会稳步增长，以满足不断增长的人口的需求。例如，2024年3月，由中国科学院上海硅酸盐研究所领导的一个中国研究团队设计了一个使用无机生物陶瓷的多细胞支架来解决肌腱到骨骼的损伤。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 运动相关损伤的发生率不断上升
    • 骨相关疾病的发生率上升
    • 科技不断进步
    • 增强身体健康意识
  • 产业陷阱与挑战
    • 肌腱炎治疗费用虚高
    • 缺乏报销场景
• 成长潜力分析
• 监管环境
• 技术景观
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 公司市占率分析
• 竞争定位矩阵

第 5 章：市场估计与预测：按处理方式，2018 - 2032

• 主要趋势
• 治疗
  • 冷热疗法
  • 物理治疗
  • 衝击波疗法
• 手术
• 药物
  • 口服
  • 专题

第 6 章：市场估计与预测：按应用分类，2018 年 - 2032 年

• 主要趋势
• 跟腱炎
• 冈上肌腱炎
• 网球肘
• 投手肘部
• 跳投者的膝盖

第 7 章：市场估计与预测：按配销通路，2018 年 - 2032 年

• 主要趋势
• 医院药房
• 零售药房
• 网路药房

第 8 章：市场估计与预测：按最终用途，2018 - 2032 年

• 主要趋势
• 医院
• 专科诊所
• 家庭护理设置
• 其他最终用户

第 9 章：市场估计与预测：按地区划分，2018 年 - 2032 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋
  • 中东和非洲其他地区

第 10 章：公司简介

• Abbott Laboratories
• AstraZeneca
• Boehringer Ingelheim Pharmaceuticals, Inc.
• Bristol Myers Squibb Company
• Colfax Corporation
• GalxoSmithKline AG
• Johnson & Johnson
• Merck and Co., Inc.
• Ossur
• Pifzer Inc.
• Stryker Corporation
• Teva Pharmaceutical Industries Ltd.
• Tynor Orthotics Pvt. Ltd
• Zimmer Biomet Holdings, Inc.

Global Tendonitis Treatment Market will witness 3.8% CAGR between 2024 and 2032, fueled by increasing research and development efforts from leading companies. With tendonitis being a prevalent condition affecting millions globally, there is a growing need for innovative treatments that offer effective relief and faster recovery.

For instance, in June 2023, Physical medicine and rehabilitation specialists at Mayo Clinic are utilizing ultrasound guidance for percutaneous tenotomies, employing a high-pressure saline stream to treat individuals with chronic tendinopathy. Referred to as percutaneous pressured hydrotenotomy, this outpatient procedure did not necessitate general anesthesia.

Leading pharmaceutical and biotech companies are investing heavily in R&D to develop novel therapies, including regenerative medicine approaches and advanced drug formulations. Additionally, technological advancements such as wearable devices and minimally invasive procedures are reshaping the landscape of tendonitis treatment. As these efforts yield promising results, the market for tendonitis treatments is poised for significant growth, offering hope for patients and driving the evolution of healthcare solutions tailored to address this common ailment.

The overall Tendonitis Treatment Industry is classified based on the treatment, application, distribution channel, end-use, and region.

The surgery segment will undergo notable development from 2024 to 2032. Surgery remains a crucial option for patients with severe or refractory tendonitis cases, particularly when conservative treatments fail to provide relief. Procedures such as percutaneous tenotomies or tendon repairs offer effective solutions for restoring tendon function and alleviating symptoms. With advancements in minimally invasive techniques and improved surgical outcomes, there is a growing preference for surgical treatments among patients and healthcare providers. As a result, the demand for surgical interventions in the tendonitis treatment market continues to expand, addressing the needs of individuals seeking long-term relief and improved quality of life.

The tendonitis treatment market share from the supraspinatus tendonitis segment will register a noteworthy CAGR from 2024 to 2032. As a common cause of shoulder pain, supraspinatus tendinitis requires effective treatment options to alleviate discomfort and restore function. Both conservative approaches, such as rest, physical therapy, and NSAIDs, as well as more advanced treatments, including corticosteroid injections or surgical interventions, are sought to address this condition. To reduce pain and improve shoulder mobility, the demand for innovative and tailored treatments targeting supraspinatus tendinitis remains high in the tendonitis treatment market.

Asia Pacific tendonitis treatment market will showcase a commendable CAGR from 2024 to 2032. With a large population and increasing prevalence of tendonitis-related conditions due to aging, physical activity, and occupational hazards, there is a growing need for effective treatment options. Moreover, rising healthcare awareness, improving access to medical facilities, and advancements in treatment modalities contribute to the expanding market demand. As healthcare infrastructure continues to develop across the Asia-Pacific region, the demand for tendonitis treatments could rise steadily to meet the needs of the growing population. For instance, in March 2024, a Chinese research group led by the Shanghai Institute of Ceramics of the Chinese Academy of Sciences devised a multicellular scaffold using inorganic bioceramics to address tendon-to-bone injuries.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data sources
  • 1.5.1 Primary
  • 1.5.2 Secondary
    • 1.5.2.1 Paid sources
    • 1.5.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of sports related injuries
    • 3.2.1.2 Rising incidence of bone related disorders
    • 3.2.1.3 Growing technological advancements
    • 3.2.1.4 Increasing awareness regarding physical fitness
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Inflated of cost of tendonitis treatment
    • 3.2.2.2 Lack of reimbursement scenario
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Porter's analysis
  • 3.6.1 Supplier power
  • 3.6.2 Buyer power
  • 3.6.3 Threat of new entrants
  • 3.6.4 Threat of substitutes
  • 3.6.5 Industry rivalry
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix

Chapter 5 Market Estimates and Forecast, By Treatment, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Therapy
  • 5.2.1 Hot & cold therapy
  • 5.2.2 Physical therapy
  • 5.2.3 Shockwave therapy
• 5.3 Surgery
• 5.4 Medications
  • 5.4.1 Oral
  • 5.4.2 Topical

Chapter 6 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Achilles tendonitis
• 6.3 Supraspinatus tendonitis
• 6.4 Tennis elbow
• 6.5 Pitcher's elbow
• 6.6 Jumper's knee

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacy
• 7.3 Retail pharmacy
• 7.4 Online pharmacy

Chapter 8 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Specialty clinics
• 8.4 Home care settings
• 8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Italy
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Abbott Laboratories
• 10.2 AstraZeneca
• 10.3 Boehringer Ingelheim Pharmaceuticals, Inc.
• 10.4 Bristol Myers Squibb Company
• 10.5 Colfax Corporation
• 10.6 GalxoSmithKline AG
• 10.7 Johnson & Johnson
• 10.8 Merck and Co., Inc.
• 10.9 Ossur
• 10.10 Pifzer Inc.
• 10.11 Stryker Corporation
• 10.12 Teva Pharmaceutical Industries Ltd.
• 10.13 Tynor Orthotics Pvt. Ltd
• 10.14 Zimmer Biomet Holdings, Inc.